argenx SE (FRA:1AE) Beneish M-Score: -1.71 (As of Jun. 26, 2026)


FRA:1AE argenx SE FRA:1AE
78 GF Score
Price €753.20
GF Value €1,204.08
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is argenx SE Beneish M-Score?

argenx SE FRA:1AE -1.02% 78 Beneish M-Score is -1.71 as of Jun. 26, 2026. GuruFocus rates FRA:1AE with a GF Score™ of 78/100 and a GF Value™ of €1,204.08 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 831 Biotechnology companies, argenx SE ranks worse than 68.59% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.71 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for argenx SE's Beneish M-Score or its related term are showing as below:

FRA:1AE' s Beneish M-Score Range Over the Past 10 Years
Min: -3.71   Med: -2.13   Max: 8.34
Current: -1.71

During the past 13 years, the highest Beneish M-Score of argenx SE was 8.34. The lowest was -3.71. And the median was -2.13.


argenx SE Beneish M-Score Historical Data

* Premium members only.

The historical data trend for argenx SE's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

argenx SE Beneish M-Score Chart

argenx SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.34 4.71 -1.00 -0.22 -1.71

argenx SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.71 0.00

FRA:1AE vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, argenx SE's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where argenx SE's Beneish M-Score falls into.


FRA:1AE
78GF Score
argenx SE FRA:1AE
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

argenx SE Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of argenx SE for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9612+0.528 * 1.0053+0.404 * 0.9716+0.892 * 1.6958+0.115 * 0.78
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6816+4.679 * 0.062407-0.327 * 1.3795
=-1.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was €1,415 Mil.
Revenue was €3,547 Mil.
Gross Profit was €3,162 Mil.
Total Current Assets was €5,892 Mil.
Total Assets was €7,415 Mil.
Property, Plant and Equipment(Net PPE) was €41 Mil.
Depreciation, Depletion and Amortization(DDA) was €24 Mil.
Selling, General, & Admin. Expense(SGA) was €1,161 Mil.
Total Current Liabilities was €1,127 Mil.
Long-Term Debt & Capital Lease Obligation was €31 Mil.
Net Income was €1,103 Mil.
Gross Profit was €55 Mil.
Cash Flow from Operations was €585 Mil.
Total Receivables was €868 Mil.
Revenue was €2,092 Mil.
Gross Profit was €1,875 Mil.
Total Current Assets was €4,663 Mil.
Total Assets was €5,923 Mil.
Property, Plant and Equipment(Net PPE) was €42 Mil.
Depreciation, Depletion and Amortization(DDA) was €17 Mil.
Selling, General, & Admin. Expense(SGA) was €1,005 Mil.
Total Current Liabilities was €640 Mil.
Long-Term Debt & Capital Lease Obligation was €31 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1415.128 / 3547.074) / (868.187 / 2091.671)
=0.398956 / 0.415069
=0.9612

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1874.61 / 2091.671) / (3162.206 / 3547.074)
=0.896226 / 0.891497
=1.0053

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (5891.835 + 41.203) / 7415.024) / (1 - (4663.363 + 41.56) / 5923.409)
=0.199863 / 0.205707
=0.9716

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3547.074 / 2091.671
=1.6958

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(16.738 / (16.738 + 41.56)) / (23.999 / (23.999 + 41.203))
=0.287111 / 0.368072
=0.78

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1161.421 / 3547.074) / (1004.84 / 2091.671)
=0.327431 / 0.480401
=0.6816

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((31.023 + 1127.439) / 7415.024) / ((31.057 + 639.77) / 5923.409)
=0.156232 / 0.11325
=1.3795

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1103.398 - 55.495 - 585.154) / 7415.024
=0.062407

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

argenx SE has a M-score of -1.71 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.71 mean?
argenx SE (FRA:1AE) has a Beneish M-Score of -1.71 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #570 out of 831 companies in the Biotechnology industry, placing it in the top 68.6%.
Is argenx SE's Beneish M-Score too high?
argenx SE's current Beneish M-Score is -1.71. Based on the distribution chart, argenx SE ranks #570 out of 831 companies in the Biotechnology industry, which is below the industry midpoint. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #570 out of 831 companies for Beneish M-Score. This places argenx SE in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on argenx SE and its competitors. argenx SE's current Beneish M-Score is -1.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (FRA:1AE) is currently considered Significantly Undervalued. The stock's GF Value™ is €1,204.08, compared to a current price of €753.20 — trading 37.4% below its estimated fair value. The current Beneish M-Score is -1.71. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For argenx SE (FRA:1AE), the current Beneish M-Score is -1.71 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is argenx SE (FRA:1AE) Overvalued in 2026?

Based on GuruFocus' analysis, argenx SE stock appears to be undervalued. The current stock price of €753.20 is trading 37.4% below its estimated GF Value™ of €1,204.08. GuruFocus considers argenx SE to be Significantly Undervalued.

Key valuation signals for FRA:1AE:

  • Beneish M-Score: -1.71
  • GF Value™: €1,204.08 vs. price of €753.20 (37.4% below fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the FRA:1AE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


argenx SE Business Description

Address Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score

Get the complete analysis for FRA:1AE

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€753.20
Price
€1,204.08
GF Value